Source comparison
BPC-157 for Climbers: Comparison of Administration Routes
Subcutaneous Injection (Near Injury) Direct local delivery to injury site; peptide diffuses through interstitial tissue 250–500 mcg daily Higher local concentration at target tissue; faster onset of localized effects Requires reconstitution and sterile injecti
This comparison does not assign a generated winner or score.
- Subcutaneous Injection (Near Injury)
- Direct local delivery to injury site; peptide diffuses through interstitial tissue
- 250–500 mcg daily
- Higher local concentration at target tissue; faster onset of localized effects
- Requires reconstitution and sterile injection technique; risk of infection if not properly executed; painful at injection site
- Most commonly used by climbers for finger pulley and elbow injuries. Offers localized targeting but carries highest user error risk due to home injection protocols
- Subcutaneous Injection (Systemic)
- Absorbed into systemic circulation; distributed via bloodstream
- Easier injection sites (abdomen, thigh); may address multiple injury sites simultaneously
- Lower local concentration at specific injury; systemic distribution uncharacterized in humans
- Less targeted than local injection; theoretical systemic effects unknown. No human pharmacokinetic data
- Oral Administration
- Absorbed through GI tract; unclear bioavailability
- 500–1000 mcg daily
- No injection required; no sterility concerns
- BPC-157 is a peptide. Likely degraded by gastric enzymes before absorption; no evidence of oral bioavailability in humans
- Theoretically convenient but mechanistically questionable. Peptides this size typically cannot survive gastric digestion intact